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Dear Editor:
Accumulating data suggest that some variants of Crohn's disease (CD) may be consequent to a Mycobacterium avium subspecies paratuberculosis (MAP) infection. Opportunely, a prospective study (Kalfus, 2013) is addressing the therapeutic role of appropriate antimycobacterial antimicrobials in CD. Potential inflammatory bowel disease (IBD) benefits may include identification of a mycobacterial etiology, improvement on current therapies, and possibly prevention.
MAP is inhibited by agents that the scientific community categorizes as anti-inflammatory (Greenstein et al., 2007) and immune-modulators. (Krishnan et al., 2009 ) A muchcited 2007 ''placebo controlled'' trial of anti-MAP antibiotics concluded that there was ''no significant role for MAP in the pathogenesis of CD'' (Selby et al., 2007) . Subsequent correspondence dismissed the possible corrupting influence of unanticipated ''immune-modulator'' anti-MAP inhibition as being ''not consistent'' with prevailing dogma. This was despite the editorial accompanying the 2007 study emphasizing significant improvement associated with concomitant use of ''immune-modulators'' (Selby et al., 2007) .
Disconcertingly, the inclusion criteria in the ongoing study (Kalfus, 2013) are essentially identical to the prior ''placebo''-controlled study (Selby et al., 2007) . Both ignore MAP inhibition by ''anti-inflammatory'' (Greenstein et al., 2007) and ''immune-modulators.'' (Krishnan et al., 2009 ) The 2007 study (Selby et al., 2007) was designed before relevant MAP inhibition data (Greenstein et al., 2007; Krishnan et al., 2009) were published. The designers of the study now recruiting (Kalfus, 2013) should explain why they ignore unrefuted published data that render their ''placebo-controlled'' study as flawed as previously (Selby et al., 2007) .
We suggest that calling the study now recruiting (Kalfus, 2013) ''placebo-controlled'' is unscientific (Greenstein et al., 2014) . Multiple medications that inhibit infectious agents (Greenstein et al., 2014) are permitted in both the ''placebo'' as well as treated groups. (Greenstein et al., 2014) . Previously, we have suggested that ''add-on studies'' is scientifically more accurate than ''placebo-controlled'' (Greenstein et al., 2014) .
A consistently flawed study design may yet again be misinterpreted as showing no added efficacy of anti-MAP agents in CD. Consequently, the potential identification of the etiology of IBD as being due to the zoonosis of MAP may irrevocably be lost.
